Dawn of a new era for patients with inflammatory bowel diseases as personalized therapeutic approach may soon be here
With its 230,000 reported cases, Canada has one of the world’s highest rates of inflammatory bowel diseases (IBD), such as Crohn’s and ulcerative colitis. A variety of drugs currently exist to treat IBD, but, at the moment, doctors have no way of knowing which drug will work best for which patient. This problem is particularly important given that many new medications are expected to hit the market in the near future.
Dr. Rioux and his team are working on tests that would enable doctors to match the right drug with the right patient, avoiding the often costly and ineffective trial-and-error approach of selecting a drug. In addition to greatly improving the quality of life of those affected, this tool, once implemented, could help save the health care system several million dollars a year by avoiding costly hospitalizations and surgeries.
To learn more about this project, click here
Co-applicants and End-users:
| Jean | Lachaine | Université de Montréal |
| Ramnik | Xavier | Mass General Hospital (Harvard), USA |
| Megan | Levings | University of British Columbia |
| Brian | White-Guay | Université de Montréal |
| Denis J. | Garand | Université Laval |
| Sophie | Veilleux | Université Laval |
| Christine | Des Rosiers | Université de Montréal |
| Sylvie | Lesage | Université de Montréal |
| Guillaume | Lettre | Montréal Heart Institute |
| Mathew | Harding | Vertex Pharmaceuticals |
| Sachdev | Sidhu | University of Toronto |
| Lawrence | Joseph | McGill University |
| Lambert | Busque | Université de Montréal |
| John | Parkinson | Vertex Pharmaceuticals |
| Josée | Parent | Association des gastro-entérologues du Québec |
| Paul | Sinclair | Canadian Association of Gastroenterology |
| Aida | Fernande | Crohn’s and Colitis Foundation of Canada |